Corbus Pharmaceuticals stock forecast
Corbus Pharmaceuticals (3371) Stock Forecast & Price Target
3371 Analyst Ratings
3371 Stock 12 Month Forecast
Average Price Target
€28.92▲(950.24% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Andres Y. Maldonado | H.C. Wainwright | €31.83 | buy | 1055.93%Upside | Reiterated | 11/16/26 | ||
| Graig Suvannavejh | Mizuho Securities | €21.83→€20.92 | buy | 659.61%Upside | Reiterated | 11/12/26 | ||
| Brian Abrahams | RBC Capital | €32.74→€30.02 | buy | 989.87%Upside | Assigned | 11/10/26 | ||
| Robert Driscoll | Wedbush | €27.29 | buy | 890.80%Upside | Reiterated | 09/15/26 | ||
| Oliver McCammon | LifeSci Capital | €34.56 | buy | 1155.01%Upside | Reiterated | 09/14/26 | ||
| Andy Hsieh | William Blair | ― | buy | ― | Reiterated | 09/14/26 | ||
| Jeff Jones | Oppenheimer | €47.30→€43.66 | buy | 1485.27%Upside | Reiterated | 08/07/26 | ||
| Paul Jeng | Guggenheim | €40.93 | buy | 1386.19%Upside | Reiterated | 06/02/26 | ||
| Maury Raycroft | Jefferies | €32.74→€30.02 | buy | 989.87%Upside | Reiterated | 05/12/26 | ||
| B. Riley Securities | €25.47 | buy | 824.74%Upside | Reiterated | 04/10/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Andres Y. MaldonadoH.C. Wainwright | BuyReiterated€31.83 | 11/16/26 | 1055.93%Upside | ||
| Graig SuvannavejhMizuho Securities | BuyReiterated€21.83→€20.92 | 11/12/26 | 659.61%Upside | ||
| Brian AbrahamsRBC Capital | BuyAssigned€32.74→€30.02 | 11/10/26 | 989.87%Upside | ||
| Robert DriscollWedbush | BuyReiterated€27.29 | 09/15/26 | 890.80%Upside | ||
| Oliver McCammonLifeSci Capital | BuyReiterated€34.56 | 09/14/26 | 1155.01%Upside | ||
| Andy HsiehWilliam Blair | BuyReiterated | 09/14/26 | ― | ||
| Jeff JonesOppenheimer | BuyReiterated€47.30→€43.66 | 08/07/26 | 1485.27%Upside | ||
| Paul JengGuggenheim | BuyReiterated€40.93 | 06/02/26 | 1386.19%Upside | ||
| Maury RaycroftJefferies | BuyReiterated€32.74→€30.02 | 05/12/26 | 989.87%Upside | ||
| BuyReiterated€25.47 | 04/10/26 | 824.74%Upside |
Best Analysts Covering Corbus Pharmaceuticals
Copying Andy Hsieh's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -6.83% per trade.
Copying Andy Hsieh's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -33.06% per trade.
Copying Andy Hsieh's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -62.02% per trade.
3371 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 19 | 12 | 12 | 13 | 10 |
| Buy | 3 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 14 | 14 | 15 | 11 |
In the current month, 3371 has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3371 average Analyst price target in the past 3 months is 28.92.
3371 Financial Forecast
3371 Earnings Forecast
Next quarter’s earnings estimate for 3371 is -EUR 1.24 with a range of -EUR 1.81 to -EUR 0.86. The previous quarter’s EPS was -EUR 1.64. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
3371 Sales Forecast
Next quarter’s sales forecast for 3371 is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

